Clover Biopharmaceuticals, Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CNY 2,451.9 million compared to CNY 6,016.3 million a year ago. Basic loss per share from continuing operations was CNY 2.22.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.47 HKD | +5.62% | +14.29% | -22.58% |
Apr. 12 | Clover Biopharmaceuticals, Ltd. announced that it has received $0.320713 million in funding | CI |
Apr. 08 | Clover Biopharmaceuticals' RSV Vaccine Candidate Shows Promise in Early Trial | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.58% | 73.88M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- 2197 Stock
- News Clover Biopharmaceuticals, Ltd.
- Clover Biopharmaceuticals, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022